- Oral presentation
- Open Access
Late gadolinium enhancement cardiovascular magnetic resonance for sudden cardiac death risk stratification in hypertrophic cardiomyopathy
Journal of Cardiovascular Magnetic Resonance volume 15, Article number: O67 (2013)
Although myocardial fibrosis identified by late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) may predict adverse outcomes among patients with hypertrophic cardiomyopathy (HCM), its precise role in risk stratification for sudden cardiac death (SCD) remains unresolved. Previous studies have relied on broad surrogate composite endpoints and were underpowered to assess SCD risk or to adjust for confounding variables. To address this, we studied the prognostic significance of LGE in a large HCM cohort with long-term follow-up.
Consecutive patients with HCM (n=711, median age 56.3 years, interquartile range [IQR] 46.7 to 66.6; 70.0% male) underwent LGE-CMR and were prospectively followed for a median of 3.5 years. This amounted to a total of 2852 patient-years of follow-up. The primary endpoint was SCD or aborted SCD. The principal secondary endpoint was a composite of cardiovascular mortality and aborted SCD. LGE imaging was performed in two orthogonal phase-encoding directions ~10 min after 0.1 mmol/kg gadolinium using an inversion recovery-prepared gradient echo sequence. The amount was quantified using the full-width at half-maximum method.
Patients with LGE had more significant left ventricular hypertrophy and lower left ventricular ejection fraction (LV-EF) than those without LGE (Table 1). The median amount of LGE in the 471 (66.2%) patients with enhancement was 5.9% of left ventricular mass (IQR: 2.2 to 13.3). At the end of follow-up, 22 patients (3.1%) reached the primary endpoint: 18 (3.8%) in the LGE group and 4 (1.7%) in the no LGE group. The amount but not the presence of fibrosis was a significant univariate predictor of SCD risk (HR per 5% LGE: 1.24, 95% CI 1.06 to 1.45; p=0.007 and HR for LGE: 2.69, 95% CI 0.91 to 7.97; p=0.073 respectively). However, on multivariate analysis, only left ventricular ejection fraction (LV-EF) remained significant (HR: 0.92, 95% CI 0.89 to 0.95; p<0.001)[Figure 1]. For the secondary composite endpoint of cardiovascular mortality and aborted SCD, 30 (6.4%) patients in the LGE group versus 8 (3.3%) in the no LGE group reached the endpoint (HR for LGE: 2.24, 95% CI 1.03 to 4.89; p=0.043). However, on multivariate analysis, only LV-EF and non-sustained VT (NSVT) emerged as a significant predictors of outcome (HR for LV-EF: 0.92, 95% CI 0.90 to 0.95, P<0.001; and HR for NSVT: 3.15, 1.37 to 7.28, p=0.007).
Neither the presence nor the amount of LGE independently predicted SCD risk after adjusting for confounders. In contrast, LV-EF was the best independent predictor of SCD and cardiovascular mortality, and should therefore be considered as part of the routine risk stratification of patients with HCM.
This work is supported by the NIHR Cardiovascular Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust, and Imperial College. Dr Ismail is supported by the British Heart Foundation.
About this article
Cite this article
Ismail, T.F., Jabbour, A., Gulati, A. et al. Late gadolinium enhancement cardiovascular magnetic resonance for sudden cardiac death risk stratification in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 15, O67 (2013). https://doi.org/10.1186/1532-429X-15-S1-O67
- Leave Ventricular Ejection Fraction
- Cardiovascular Magnetic Resonance
- Sudden Cardiac Death
- Late Gadolinium Enhancement
- Hypertrophic Cardiomyopathy